BIOCYTOGEN-B (02135) surged over 7% during afternoon trading sessions. As of press time, the stock was up 4.07% to HK$26.58, with a trading volume of HK$16.74 million.

On the news front, BIOCYTOGEN announced on September 16 that it has signed an antibody licensing agreement with German ADC development company Tubulis. Under this agreement, Tubulis will leverage BIOCYTOGEN's proprietary RenMice fully human antibody development platform, combining it with Tubulis' proprietary linker and payload technologies to develop innovative ADC therapies. According to the agreement terms, BIOCYTOGEN will receive an upfront payment and is entitled to development, regulatory, and commercialization milestone payments, as well as single-digit net sales royalties.

Notably, on September 4, BIOCYTOGEN had just signed an antibody option and evaluation agreement with Merck Germany. Under this agreement, Merck seeks to evaluate fully human antibodies developed through BIOCYTOGEN's RenMice platform to jointly develop cutting-edge solutions including antibody-conjugated lipid nanoparticles (LNPs) for nucleic acid drug delivery.

BIOCYTOGEN Chairman and CEO Shen Yuelei stated that Tubulis exercising its option, along with the agreement with Merck, both demonstrate the international competitiveness and drug translation potential of the fully human antibody platform.